Diphtheria toxin CRM197

[Description]:

Diphtheria toxin CRM197, a nontoxic variant of diphtheria toxin, has a single mutation (Glycine to Glutamate substitution at position 52) that eliminates its toxicity. CRM197 is widely used as a carrier protein in conjugate vaccines[1].

[Related Catalog]:

Research Areas >> Infection

Signaling Pathways >> Others >> Others

[In Vitro]

Diphtheria toxin CRM197 is an enzymatically inactive and nontoxic form of diphtheria toxin that contains a single amino acid substitution (G52E). Being naturally nontoxic, CRM197 is an ideal carrier protein for conjugate vaccines against encapsulated bacteria and is currently used to vaccinate children globally against Haemophilus influenzae, pneumococcus, and meningococcus[1][2]. Diphtheria toxin, a single polypeptide secreted by lysogenic strains of Corynebacterium diphtheria, causes the disease diphtheria in humans by gaining entry into the cytoplasm of cells and inhibiting protein synthesis[3][4].

[References]

[1]. Ravi P N Mishra, et al. Structural and Immunological Characterization of E. coli Derived Recombinant CRM 197 Protein Used as Carrier in Conjugate Vaccines. Biosci Rep. 2018 Sep 25;38(5):BSR20180238.

[2]. Enrico Malito, et al. Structural Basis for Lack of Toxicity of the Diphtheria Toxin Mutant CRM197. Proc Natl Acad Sci U S A. 2012 Apr 3;109(14):5229-34.

[3]. C E Bell, et al. Crystal Structure of Diphtheria Toxin Bound to Nicotinamide Adenine Dinucleotide. Biochemistry. 1996 Jan 30;35(4):1137-49.

[4]. Ranjit Sah, et al. Diphtheria. N Engl J Med. 2019 Sep 26;381(13):1267.

[ Appearance of Characters ]:
lyophilized powder

[ Storage condition ]:
2-8°C

[ Symbol ]:

GHS06

[ Signal Word ]:
Danger

[ Hazard Statements ]:
H300

[ Precautionary Statements ]:
Missing Phrase - N15.00950417

[ Personal Protective Equipment ]:
Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter

[ Hazard Codes ]:
T+

[ Risk Phrases ]:
28

[ Safety Phrases ]:
22-24/25-45-36/37-28

[ RIDADR ]:
3172

[ WGK Germany ]:
3

[ RTECS ]:
XW5807200

[ Packaging Group ]:
I

[ Hazard Class ]:
6.1(a)

Carbohydrate-based vaccines with a glycolipid adjuvant for breast cancer.

Proc. Natl. Acad. Sci. U. S. A. 110(7) , 2517-22, (2013)

Globo H (GH) is a hexasaccharide specifically overexpressed on a variety of cancer cells and therefore, a good candidate for cancer vaccine development. To identify the optimal carrier and adjuvant co...

Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules.

Expert Rev. Vaccines 10(11) , 1621-31, (2011)

Conjugate vaccines using diphtheria toxoid variant (CRM(197)), diphtheria toxoid and tetanus toxoid (TT) as carrier protein may induce immune interactions (interference or impairment as measured by lo...

Antitumor effects of CRM197, a specific inhibitor of HB-EGF, in T-cell acute lymphoblastic leukemia.

Anticancer Res. 31(7) , 2483-8, (2011)

The therapeutic outcome for T-cell acute lymphoblastic leukemia (T-ALL) remains poor; thus, novel, targeted therapies are urgently needed. Recently, we showed that heparin-binding epidermal growth fac...

Names

Biological Activity

Chemical & Physical Properties

Safety Information

Articles

Related Compounds